A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer
Fig 2
(A) Cumulative disease-free survival (DFS) and (B) overall survival (OS) rates of the 298 colorectal cancer patients calculated using the Kaplan—Meier method.
Positive biochip results correlated strongly with lower DFS and OS rates of colorectal cancer patients (both P < 0.001).